Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUY4VV)

Drug Name
PRA023 Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Ulcerative colitis DD71 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMUY4VV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Vascular endothelial cell growth inhibitor (TNFSF15)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TEV-48574 DMHWN63 Crohn disease DD70 Phase 2 [4]
PF-07261271 DM0K4WQ Inflammatory bowel disease DD72 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial cell growth inhibitor (TNFSF15) TTEST6I TNF15_HUMAN Not Available [3]

References

1 ClinicalTrials.gov (NCT05013905) A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04996797) A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of Prometheus Biosciences
4 Clinical pipeline report, company report or official report of Teva Pharmaceutical
5 Clinical pipeline report, company report or official report of Pfizer